Business
ECOVAXXIN® MS EU marketing authorisation granted
ECO Animal Health Group plc has received EU marketing authorisation for its poultry vaccine ECOVAXXIN® MS, which targets Mycoplasma synoviae infections and aims to reduce air-sac and foot-pad lesions and egg production losses, potentially impacting laying hens by 5-10%. This authorisation was granted over a month earlier than expected, following a positive opinion in November 2025, and represents the first commercial launch from the company's R&D portfolio. ECO Animal Health plans to provide further details on the EU commercial launch in early 2026. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n22 December 2025\n\n \nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nEU marketing authorisation granted for ECOVAXXIN® MS\n \nECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the European Commission has adopted a decision granting EU marketing authorisation (MA) for ECOVAXXIN® MS, the Company's poultry vaccine against Mycoplasma synoviae.\n \nThe MA has been issued over a month earlier than anticipated following the Committee for Medicinal Products for Veterinary Use's Positive Opinion in November 2025.\n \nECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions and egg production losses caused by Mycoplasma synoviae infections. The infection causes economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.\n \nThe Company will issue an update to the market in early 2026 to provide further details on its plans for the EU commercial launch of ECOVAXXIN® MS.\n \nDavid Hallas, Chief Executive Officer of ECO Animal Health, said: \"We are delighted to have received EU marketing authorisation for ECOVAXXIN MS, over a month ahead of schedule. This is a key milestone for ECO, enabling the first commercial launch from our innovative R&D portfolio, and reflects the high-quality work from our R&D, regulatory, marketing, and technical teams.\n \n\"We look forward to updating the market early in 2026 to provide more detail on our plans for the commercial launch of this important vaccine.\"\n \n-Ends- \nContacts\n \n\n\n\n\nECO Animal Health Group plc\nDavid Hallas (Chief Executive Officer)\nChristopher Wilks (Chief Financial Officer)\n \n\n\n020 8447 8899\n\n\n\n\nICR Healthcare (Financial PR)\nMary-Jane Elliott\nJessica Hodgson\n\n\n020 3709 5700\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Joint Broker)\nPhilip Davies\nSamed Ethemi\n \n\n\n020 7496 3000\n\n\n\n\nPanmure Liberum (Joint Broker)\nEmma Earl\nWill Goode\nMark Rogers\nRupert Dearden\n \n\n\n020 3100 2000 \n\n\n\n\nEq...